PODD · News · 20260805N

Type 2 Diabetes Retention

INSULET CORP · 2026-08-05 · Importance 40 · Surprise 42

Insulet reported weaker-than-expected retention and utilization among U.S. Type 2 diabetes patients using Omnipod. The company attributed the issue to execution challenges during the initial 90-day onboarding period, which weakened the expected expansion of Omnipod into the Type 2 market. Insulet is responding by expanding customer care, changing sales-force compensation, refining sampling, and rolling out the Omnipod Discover platform.

Key facts

• Management attributed Type 2 retention issues to execution challenges in the initial 90-day onboarding period. source